Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial - Hueber, W; Sands, B E; Lewitzky, S; Secukinumab in Crohn's Disease Study Group (Gut, 2012)